A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine

Get answers to your Hodgkin's Disease questions.
Dr. Kimball’s Bio | Q&A Archive
Lymphoma - Hodgkin's; Hodgkin's lymphoma; Hodgkins disease; HD
Hodgkin's Disease
Hodgkin's disease is a lymphoma, a cancer of the lymphatic system. Hodgkin's disease and non-Hodgkin's lymphoma are the two types of lymphomas. Hodgkin's disease is distinguished by the presence of large abnormal cells, called Reed-Sternberg cells. The disease is less common than non-Hodgkin's lymphoma.
Hodgkin's disease is classified into two main types:
Prognosis
Hodgkin's disease is considered one of the most curable forms of cancer, especially if it is diagnosed and treated early. Five-year survival rates for patients diagnosed with stage I or stage II Hodgkin's disease are 90 - 95%. Many patients with late-stage Hodgkin's disease also have good odds for survival.
Risk Factors
Hodgkin's disease occurs most often in people ages 15 - 40 (especially in their 20s), and in people over age 55. About 10 - 15% of Hodgkin's disease cases are diagnosed in children and teenagers. It is slightly more common in males than in females.
Certain types of viral infections may increase the risk of Hodgkin's disease. Infectious mononucleosis, which is caused by the Epstein-Barr virus, is associated with increased risk as is infection with the human immunodeficiency virus (HIV).
Treatment
Chemotherapy and radiation are the main treatments for Hodgkin's disease. Patients who have relapsed may be treated with autologous stem cell transplantation.
Preventing Infection after Cancer Treatment
Both chemotherapy and stem cell transplants increase the risk for serious infections. Patients must take precautions to avoid exposure to germs. Ways to prevent infection include:
American Cancer Society. Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society, 2008.
Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008;111 (6): 2977-83.
Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27.
Horning SJ. Hodgkin’s lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKena WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2008:chap 111.
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 Feb 10;25(5):571-8. Epub 2007 Jan 22.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Disease / Lymphoma. V.2.2009.
Oeffinger KC, Ford JS, Moskowitz CS, Diller LR, Hudson MM, Chou JF, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA. 2009 Jan 28;301(4):404-14.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.800.492.5538